The sarclisa market research report is one of a series of new reports that provides sarclisa market statistics, including sarclisa industry global market size, regional shares, competitors with a sarclisa market share, detailed sarclisa market segments, market trends and opportunities, and any further data you may need to thrive in the sarclisa industry. This sarclisa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to growth of personalized medicine, shift toward immunotherapies, increasing prevalence of autoimmune diseases, growing focus on long-term remission, and awareness of hematological malignancies. Major trends in the forecast period include shift towards more targeted therapies, launch of biosimilars, advancements in molecular diagnostics, technological advancements in cancer diagnosis, and innovation in targeted cancer therapies.
The increasing prevalence of cancer is expected to drive the growth of the Sarclisa market. Cancer is a group of diseases characterized by uncontrolled cell growth and division, which can invade surrounding tissues and spread to other parts of the body. Factors contributing to the rising prevalence of cancer include an aging population, lifestyle choices, environmental exposures, genetic predispositions, and improved detection methods. Sarclisa plays a crucial role in treating cancer, particularly multiple myeloma, by targeting and eliminating cancerous plasma cells, strengthening the immune system’s ability to fight the disease, and improving treatment outcomes. For example, in February 2024, the World Health Organization reported that in 2022, there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally. The most prevalent cancer types were lung, breast, and colorectal cancers. Projections suggest that by 2050, new cancer cases could exceed 35 million, a 77% increase from 2022, further driving the demand for effective treatments such as Sarclisa.
The growth of the geriatric population is also expected to boost the Sarclisa market. The geriatric population, typically those aged 65 and above, faces various health, social, and economic challenges as they age. Factors such as longer life expectancy, advances in healthcare, and declining birth rates are contributing to a growing global elderly population. Sarclisa is particularly important for older adults, especially those with multiple myeloma who may not be eligible for more intensive treatments such as autologous stem cell transplants. According to the World Health Organization, it is expected that by 2030, one in six people worldwide will be 60 years of age or older, with the number of individuals over 60 growing from 1 billion in 2020 to 1.4 billion by 2030, and doubling to 2.1 billion by 2050. This demographic shift will contribute to the increasing demand for treatments such as Sarclisa.
A key trend in the Sarclisa market is the approval of new drug indications for treating adult patients with newly diagnosed multiple myeloma. Drug approval involves evaluating a drug’s safety, efficacy, and quality through clinical trials, enabling it to be marketed for use. In September 2024, Sanofi SA announced that the U.S. Food and Drug Administration (FDA) had approved Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This approval follows the positive results of the IMROZ phase 3 study, which showed that the combination of Sarclisa and VRd reduced the risk of disease progression or death by 40% compared to VRd alone. This marks Sarclisa’s third indication and highlights Sanofi’s commitment to addressing an unmet need in the treatment of multiple myeloma.
The key company operating in the sarclisa market is Sanofi S.A.
North America was the largest region in the sarclisa market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sarclisa report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the sarclisa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Sarclisa is a monoclonal antibody used to treat certain cancers, specifically multiple myeloma, a type of blood cancer. It works by targeting and binding to CD38, a protein present on the surface of multiple myeloma cells. By binding to CD38, Sarclisa enhances the immune system’s ability to recognize and eliminate these cancerous cells. It is typically used in combination with other cancer therapies to improve treatment outcomes.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main formulations of Sarclisa are an injectable solution and a lyophilized powder for injection. It is indicated for the treatment of relapsed or refractory multiple myeloma, a stage in which the disease either returns after initial treatment or no longer responds to therapy, as well as newly diagnosed multiple myeloma. Sarclisa is distributed through both hospital and retail pharmacies.
The sarclisa market consists of sales of chemotherapy agents, immunotherapy drugs, biosimilars, and diagnostic kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to growth of personalized medicine, shift toward immunotherapies, increasing prevalence of autoimmune diseases, growing focus on long-term remission, and awareness of hematological malignancies. Major trends in the forecast period include shift towards more targeted therapies, launch of biosimilars, advancements in molecular diagnostics, technological advancements in cancer diagnosis, and innovation in targeted cancer therapies.
The increasing prevalence of cancer is expected to drive the growth of the Sarclisa market. Cancer is a group of diseases characterized by uncontrolled cell growth and division, which can invade surrounding tissues and spread to other parts of the body. Factors contributing to the rising prevalence of cancer include an aging population, lifestyle choices, environmental exposures, genetic predispositions, and improved detection methods. Sarclisa plays a crucial role in treating cancer, particularly multiple myeloma, by targeting and eliminating cancerous plasma cells, strengthening the immune system’s ability to fight the disease, and improving treatment outcomes. For example, in February 2024, the World Health Organization reported that in 2022, there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally. The most prevalent cancer types were lung, breast, and colorectal cancers. Projections suggest that by 2050, new cancer cases could exceed 35 million, a 77% increase from 2022, further driving the demand for effective treatments such as Sarclisa.
The growth of the geriatric population is also expected to boost the Sarclisa market. The geriatric population, typically those aged 65 and above, faces various health, social, and economic challenges as they age. Factors such as longer life expectancy, advances in healthcare, and declining birth rates are contributing to a growing global elderly population. Sarclisa is particularly important for older adults, especially those with multiple myeloma who may not be eligible for more intensive treatments such as autologous stem cell transplants. According to the World Health Organization, it is expected that by 2030, one in six people worldwide will be 60 years of age or older, with the number of individuals over 60 growing from 1 billion in 2020 to 1.4 billion by 2030, and doubling to 2.1 billion by 2050. This demographic shift will contribute to the increasing demand for treatments such as Sarclisa.
A key trend in the Sarclisa market is the approval of new drug indications for treating adult patients with newly diagnosed multiple myeloma. Drug approval involves evaluating a drug’s safety, efficacy, and quality through clinical trials, enabling it to be marketed for use. In September 2024, Sanofi SA announced that the U.S. Food and Drug Administration (FDA) had approved Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This approval follows the positive results of the IMROZ phase 3 study, which showed that the combination of Sarclisa and VRd reduced the risk of disease progression or death by 40% compared to VRd alone. This marks Sarclisa’s third indication and highlights Sanofi’s commitment to addressing an unmet need in the treatment of multiple myeloma.
The key company operating in the sarclisa market is Sanofi S.A.
North America was the largest region in the sarclisa market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sarclisa report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the sarclisa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Sarclisa is a monoclonal antibody used to treat certain cancers, specifically multiple myeloma, a type of blood cancer. It works by targeting and binding to CD38, a protein present on the surface of multiple myeloma cells. By binding to CD38, Sarclisa enhances the immune system’s ability to recognize and eliminate these cancerous cells. It is typically used in combination with other cancer therapies to improve treatment outcomes.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main formulations of Sarclisa are an injectable solution and a lyophilized powder for injection. It is indicated for the treatment of relapsed or refractory multiple myeloma, a stage in which the disease either returns after initial treatment or no longer responds to therapy, as well as newly diagnosed multiple myeloma. Sarclisa is distributed through both hospital and retail pharmacies.
The sarclisa market consists of sales of chemotherapy agents, immunotherapy drugs, biosimilars, and diagnostic kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Sarclisa Market Characteristics4. Sarclisa Market Trends And Strategies5. Sarclisa Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Sarclisa Pricing Analysis & Forecasts30. Global Sarclisa Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Sarclisa Market32. Recent Developments In The Sarclisa Market
3. Sarclisa Market Biologic Drug Characteristics
6. Global Sarclisa Growth Analysis And Strategic Analysis Framework
8. Sarclisa Market Segmentation
9. Global Sarclisa Epidemiology Of Clinical Indications
10. Sarclisa Market Regional And Country Analysis
11. Asia-Pacific Sarclisa Market
12. China Sarclisa Market
13. India Sarclisa Market
14. Japan Sarclisa Market
15. Australia Sarclisa Market
16. South Korea Sarclisa Market
17. Western Europe Sarclisa Market
18. UK Sarclisa Market
19. Germany Sarclisa Market
20. France Sarclisa Market
21. Eastern Europe Sarclisa Market
22. North America Sarclisa Market
23. USA Sarclisa Market
24. Canada Sarclisa Market
25. South America Sarclisa Market
26. Middle East Sarclisa Market
27. Africa Sarclisa Market
28. Sarclisa Market Competitive Landscape And Company Profiles
29. Global Sarclisa Market Pipeline Analysis
33. Sarclisa Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Sarclisa Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on sarclisa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for sarclisa ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sarclisa market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Formulation: Injectable Solution; Lyophilized Powder for Injection2) By Clinical Indication: Relapsed Or Refractory Multiple Myeloma; Newly Diagnosed Multiple Myeloma
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
Key Companies Profiled: Sanofi S.A.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi S.A.
